| 摘要: |
| 吉非替尼为靶向性表皮生长因子受体(EGFR)酪氨酸激酶抑制剂,2005年批准进口中国用于治疗局部晚期及或转移性非小细胞肺癌(NSCLC),其疗效好且血液系统不良反应较少,最常见的不良反应为腹泻和皮肤反应。2015年7月13日,美国FDA批准吉非替尼用于一线治疗转移性NSCLC患者一线治疗,针对用于EGFR基因突变的患者。本文主要综述其近年国内外的临床研究进展。 |
| 关键词: 吉非替尼 抗肿瘤 临床研究 |
| DOI:10.13506/j.cnki.jpr.2017.04.015 |
| 基金项目: |
|
|
|
| Clinical application of Gefitinib |
| YANG Tongjiang,WANG Quanliang,XIE Lili,SHAN Yanqiang |
| (Qilu Pharmaceutical Co.,Ltd.,Haikou 570314, China) |
| Abstract: |
| Gefitinib is an EGFR inhibitor. It is only effective in cancers with mutated and overactive EGFR. The CFDA approved gefitinib in 2005 for non-small cell lung cancer (NSCLC). It was approved as monotherapy for the treatment of patients with locally advanced or metastatic NSCLC after failure of both platinum-based and docetaxel chemotherapies.On July 13,2015,FDA approved as a first-line treatment for NSCLC.The advancement of gefitinib in current clinic researches were reviewed in this article. |
| Key words: Gefitinib Anticancer Clinical progress |